Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Biocon Ltd News Today

370.45
(2.18%)
Feb 1, 2025|03:59:25 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Company

Sectoral

Biocon Q3 Revenue Up 10%, EBITDA Rises 16%

Biocon's EBITDA increased by 16% YoY to ₹787 crore, which shows improved operational performance.

31 Jan 2025|11:07 AM
Top Stocks for Today - 13th January 2025

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Just Dial, PCBL, etc.

13 Jan 2025|07:29 AM
Biocon unit gets approval for Tacrolimus capsules in China

The approval further adds to Biocon's portfolio of complex drug products and will be commercialised in the region expeditiously

3 Jan 2025|09:44 AM
Top Stocks for 3rd January 2025

Here are some of the stocks that may see significant price movement today: Varun Beverages, NHPC, Hindustan Zinc, etc.

3 Jan 2025|07:01 AM
Biocon Gets USFDA Clearance and EU Nod for Diabetes Drug

The USFDA released an Establishment Inspection Report with a "Voluntary Action Indicated" status for Biocon's Active Pharmaceutical Ingredients facility in Bengaluru.

27 Dec 2024|03:28 PM
Top Stocks for today - 16th December 2024

Here are some of the stocks that may see significant price movement today: Reliance Industries, Biocon, Bharat Forge, etc.

16 Dec 2024|07:20 AM
Top Stocks for today - 9th December 2024

Here are some of the stocks that may see significant price movement: Godrej Consumer Products, Biocon, Paytm, etc.

9 Dec 2024|07:21 AM
Biocon Secures FDA Approval for Innovative Autoimmune Drug YESINTEK

YESINTEK targets specific proteins that trigger inflammation, which presents new therapeutic options in the chronic management of autoimmune diseases.

1 Dec 2024|11:20 PM
Biocon Biologics collaborates with Diabetes Africa

Ethiopia, with a prevalence of 2-3%, is one of the top four nations in Sub-Saharan Africa for adult diabetics.

28 Nov 2024|03:12 PM
Biocon Shares Surge on USFDA VAI Designation

The combined cGMP inspection and pre-licensing inspection (PLI), which took place between July 15 and July 26, 2024, is the subject of this update.

11 Nov 2024|12:27 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.